IMMU Share Price Performance
SEK 7.35
-0.68 (-8.47%)
77.7% undervalued intrinsic discount
SEK 33.00
Fair Value
Price SEK 7.35
AnalystConsensusTarget SEK 33.00
AnalystHighTarget SEK 50.00
Fair ValueSEK 33.00
Share Pricen/a
Mendus AB (publ) Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
IMMU Community Narratives
AN
Fair Value
·Fair Value SEK 33 77.7% undervalued intrinsic discount
Post Remission Myeloid Cancer Focus Will Support Future Opportunity For This Biotech
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value SEK 50 85.3% undervalued intrinsic discount
Post Remission Immunotherapy Pipeline Will Transform Long Term Prospects For This Cancer Developer
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Mendus
77.7% undervalued intrinsic discount
Post Remission Myeloid Cancer Focus Will Support Future Opportunity For This Biotech
View narrativeAN
Updated 28 Jul
Mendus
85.3% undervalued intrinsic discount
Post Remission Immunotherapy Pipeline Will Transform Long Term Prospects For This Cancer Developer
View narrativeAN
Published 29 Jul
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Post Remission Immunotherapy Pipeline Will Transform Long Term Prospects For This Cancer Developer
Fair Value: SEK 50 85.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IMMU: Future Trial Progress In Leukemia Will Drive Bullish Repricing
Fair Value: SEK 33 77.7% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Mendus AB (publ) Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 11, 2026
- -1.55
- 0%
- 0%
- 0.2%
About IMMU
- Founded
- 2002
- Employees
- 19
- CEO
- WebsiteView website
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company’s lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
